AMGN is trading below its 50‑day moving average with RSI near 42 and shrinking volume, indicating weak momentum. Fundamentals still lag earnings expectations, so the outlook stays bearish.

Broad market weakness and a bullish focus on Eli Lilly leave Amgen without headline support, keeping investor sentiment cautious. The stock is likely to remain under pressure.

Long‑term risk is heightened by competitive pipeline moves like Xencor’s advances and Amgen’s modest growth outlook. Without a clear innovation catalyst, downside risk dominates.

Technical signals show MACD below its signal line, negative 20‑day momentum, and price testing resistance near $380, all pointing to further downside. Data‑driven models therefore stay bearish.